Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGB-R04 in Adult Hemophilia B (Phase I/II, China)
CTR20221462Phase 2Terminated
- Sponsor
- Shanghai Tianze Yuntai Biopharmaceutical
- Start
- Jul 2022
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of VGB-R04 in hemophilia B (HB), sponsored by Shanghai Tianze Yuntai Biopharmaceutical. Started Jul 2022; status: terminated.
02
Drugs
VGB-R04
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on CTR20221462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221462.